Home » Topics » Disease categories and therapies » Immune

Immune
RSS

New agents for autoimmune disorders and transplant rejection imparted in recent patent literature

Dec. 19, 2007

Novel immunosuppressant agents disclosed in recent Actelion patent

Dec. 14, 2007

DOR BioPharma seeks approval for orBec NDA

Dec. 12, 2007

FDA grants fast track designation to Osiris' Prochymal for acute GVHD

Dec. 12, 2007

FDA approves Medarex's two IND applications for MDX-1342 in CLL and arthritis

Dec. 10, 2007

LifeCycle Pharma initiates phase II clinical trial of immunosuppressant LCP-Tacro

Dec. 7, 2007

DOR BioPharma enters named patient access program with Orphan Australia for orBec

Dec. 4, 2007

LifeCycle initiates phase I clinical trial of sirolimus for organ rejection after transplantation

Dec. 3, 2007

In vivo activity of novel agent for transplant rejection profiled at AstraZeneca

Nov. 30, 2007

MenACWY meningitis vaccine well tolerated, immunogenic in infants

Nov. 29, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...